Host: Jacob Sands, MD
Guest: Liza Villaruz, MD
According to a recent study, the immune checkpoint inhibitor durvalumab is not only considered safe, but it may also offer overall survival benefits for individuals with advanced or metastatic non-small cell lung cancer (NSCLC) and restricted performance status. Here to talk about this research are Dr. Jacob Sands and Dr. Liza Villaruz, Associate Professor of Medicine at the University of Pittsburgh School of Medicine.
